Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

Core Viewpoint - Aptose Biosciences Inc. has announced the rescheduling of its special meeting of shareholders originally set for January 16, 2026, to a later date, pending final clearance of the proxy statement from the SEC [1][2]. Group 1: Meeting Rescheduling - The special meeting will be held as soon as practicable in January 2026, with no changes to the record date of December 12, 2025, or the matters to be discussed, including the continuance under the ABCA and the acquisition by HS North America Ltd. [1][2] - The new date, time, and virtual details for the meeting will be announced after receiving SEC clearance [2]. Group 2: Transaction Details - The meeting will address the continuance of Aptose from the Canada Business Corporations Act to the ABCA and the acquisition by Hanmi Pharmaceutical Co. Ltd. through a statutory plan of arrangement [1][3]. - The board of directors recommends that shareholders vote in favor of the special resolutions for the continuance and the arrangement [3]. Group 3: Company Overview - Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor showing efficacy in treating relapsed or refractory acute myeloid leukemia (AML) and is being developed for frontline therapy in newly diagnosed AML [4].